Navigation Links
Boehringer Ingelheim Announces Equine Research Awards

ST. JOSEPH, Mo., Dec. 3, 2012 /PRNewswire/ -- Researchers at two universities will be studying equine pigeon fever (Corynebacterium pseudotuberculosis) as recipients of the 2012 Advancement of Equine Research Awards, sponsored by Boehringer Ingelheim Vetmedica, Inc. (BIVI).


Proposals by Roberta R. Pollock, Ph.D., professor of biology at Occidental College, and Allison J. Stewart, BVSc, professor of equine internal medicine at Auburn University, were selected by a panel of equine practitioners and university professors and researchers in veterinary medicine. Each award will provide $25,000 for 12-month research programs at each institution. The research awards were announced during the recent 2012 American Association of Equine Practitioners Annual Convention in Anaheim, Calif.

"The quality of equine research proposals this year was exceptional," says Steve Grubbs, DVM, PhD, DACVIM equine professional services, BIVI. "Although this is an academic award, the top priority is to identify projects that ultimately can improve the quality of life for horses and their owners."

Dr. Pollock will focus her efforts on combining equine disease infection studies with a mouse model for pigeon fever to identify and clone protective protein antigens from Corynebacterium pseudotuberculosis. Areas of research will include the pathophysiology of Corynebacterium pseudotuberculosis and development of an equine challenge model, and comparison of host immunity between infections resulting in internal infection and recurrent infection in recovered horses.

Dr. Stewart, assisted by graduate student Marta Barbra Recreo, will look into the transmission of Corynebacterium pseudotuberculosis in horses by houseflies. Like Dr. Pollock, she will focus on pathophysiology and a challenge model, as well as seasonality of Corynebacterium pseudotuberculosis infection and studies of insect vectors.

The topic for the 2013 awards will be announced next spring. Veterinarians, diagnosticians, and public and private researchers in the United States and Canada are eligible to submit proposals. Awards will be selected based on established criteria, including potential impact on the equine industry; originality and scientific quality; and probability of success in completing the yearlong studies.

"I am encouraged by the quality of the proposals submitted this year," Dr. Grubbs says. "BIVI is proud to take a leading role in helping provide equine health solutions, but we would not be nearly as successful without the ongoing research conducted by dedicated research and veterinary medical professionals around the country."

For more information and complete submission instructions, please visit

About Boehringer Ingelheim

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 44,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel medications of high therapeutic value for human and veterinary medicine.

As a central element of its culture, Boehringer Ingelheim pledges to act socially responsible. Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect, as well as environmental protection and sustainability are intrinsic factors in all of Boehringer Ingelheim's endeavours.

In 2011, Boehringer Ingelheim achieved net sales of about $17.1 billion (13.2 billion euro). R&D expenditure in the business area Prescription Medicines corresponds to 23.5% of its net sales.

For more information, please visit and follow us on Twitter at

SOURCE Boehringer Ingelheim
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Phase 2b Data of Boehringer Ingelheims Interferon-Free Hepatitis C Treatment Show Viral Cure Achieved in Up to 85% of Treatment-Naive Patients
2. Whistleblowers extraordinary efforts helped win $95 million settlement with Boehringer Ingelheim
3. Boehringer Ingelheim announces afatinib expanded access program (EAP) for patients with EGFR mutation-positive advanced NSCLC
4. Boehringer Ingelheim and Lilly introduce the My Well Planner Lifestyle Improvement Program for Adults with Type 2 Diabetes
5. Lilly and Boehringer Ingelheim Present Data at the 72nd American Diabetes Association Scientific Sessions® from Phase II Studies Comparing Investigational Novel Basal Insulin to Insulin Glargine
6. Boehringer Ingelheim Presents First Data for Tiotropium in Adolescents with Moderate Persistent Asthma
7. Results of Phase II Study of Boehringer Ingelheims Investigational Bronchodilator for COPD Presented at 2012 ATS International Conference
8. Boehringer Ingelheim to present pivotal Phase III results for afatinib in first-line treatment of EGFR mutation-positive NSCLC at ASCO 2012
9. New Data to be Presented at the Annual American Thoracic Society International Conference Demonstrates Depth of Boehringer Ingelheim Respiratory Research Pipeline
10. Boehringer Ingelheim Announces Launch of GLORIA™-AF Registry in Newly-Diagnosed Patients with Non-Valvular Atrial Fibrillation
11. Bernstein Liebhard LLP Announces That A Class Action Has Been Filed Against Abiomed, Inc.
Post Your Comments:
(Date:11/25/2015)... 25, 2015 - Will Also ... (CME) --> - Will ... Education (CME) --> - Will ... Continuing Medical Education (CME) Elsevier , ... services, will feature latest diagnostic imaging textbooks and decision support tools, ...
(Date:11/24/2015)... 25, 2015 The hope of ... failure of IVF cycles. After failure of over 15 ... had lost all hopes that she would be able to conceive ever. But finally optimism ... conceived after failure of over 15 IVF cycles. ... they decided to take one last attempt with Gaudium IVF Center in ...
(Date:11/24/2015)... 24, 2015  Array BioPharma Inc. (Nasdaq: ... Officer, Ron Squarer , will present at ... York.  The public is welcome to participate in ... BioPharma website.Event:Piper Jaffray Annual Healthcare ConferencePresenter:  , Ron ... 2015Time:1:30 p.m. Eastern Time Webcast: , ...
Breaking Medicine Technology:
(Date:11/25/2015)... IL (PRWEB) , ... November 25, 2015 , ... ... to six decades of music, friendships, and learning in its 65th Anniversary Brillianteen ... held Dec. 5-6. , For 65 years, Brillianteen has been a ...
(Date:11/25/2015)... , ... November 25, 2015 , ... Today, Mothers ... our nation’s roadways has dropped below 10,000 for the first time since 2011. In ... 2013. , According to data released by the National Highway Traffic Safety Administration (NHTSA), ...
(Date:11/25/2015)... ... November 25, 2015 , ... "When ... that regular bras were incredibly uncomfortable," said an inventor from Bronx, N.Y. "In ... She developed the patent-pending RECOVERY BRA for added comfort and support. The bra ...
(Date:11/25/2015)... ... , ... Many people know of the common symptoms of low thyroid hormone ... But many people who find their cholesterol levels and weight are creeping up are ... if they don’t have any of the other symptoms. , Thyroid hormone plays a ...
(Date:11/25/2015)... ... November 25, 2015 , ... Students and parents have something to be thankful ... Create Real Impact awards. California Casualty is proud to support the contest ... distracted and reckless driving, the number one killer of young drivers. , Almost ...
Breaking Medicine News(10 mins):